Loading institutional data...
Loading institutional data...
Held by 1,402 of 5,944 reporting institutions (99th percentile) — extremely crowded.
Data as of Q1 2026
Loading snapshot...
Loading financials...
Loading valuation...
Loading quality & risk...
Loading dividends & returns...
Loading capital allocation...
Loading debt & leverage...
Loading performance...
Loading peer comparison...
Loading ownership map...
Loading crowding analysis...
Loading conviction analysis...
Loading buy/sell flow...
Loading ownership trends...
Loading top holders...
Loading top holders...
Solve the discounted cash flow backwards, then stress-test the assumptions.
This company doesn't have positive free cash flow, so a reverse DCF can't be run.
Total shares institutions bought (green) vs sold (red) each quarter across all holders.
Inferred from quarter-over-quarter change in each fund's 13F position (new stakes count as buys, exits as sells). Not tick-level trades.
Total return (dividends reinvested) vs the market, from quarter-end prices.
Above 0 = ahead of the S&P 500 since the window start; below 0 = behind. Rising means it's pulling ahead.
How far the stock fell below its prior peak. Deeper, longer drawdowns = a rougher ride to the same return.
Quarter-end, dividend-adjusted (total return). Beta & volatility from quarterly returns (annualized). Benchmark is the S&P 500 (SPY total return). Annual returns compound the quarters ending in each calendar year; the first and last years in a window may be partial. Past performance doesn't predict future results.
Ranked against 1085 sector peers with collected financials. Valuation from latest close × latest fiscal-year fundamentals; 13F conviction as of 2026-03-31.
Percentile is “goodness” within the peer set (100 = best). For valuation and leverage that means cheaper / less-levered ranks higher.
| Company | Mkt cap ▼ | P/E | EV/EBITDA | P/S | Rev gr | Gross | Net | ROE | ROIC | Net D/EBITDA | 13F |
|---|---|---|---|---|---|---|---|---|---|---|---|
| BCAX | $1.24T | — | — | — | — | — | — | -34.4% | -34.4% | — | 143 |
| LLY | $1.03T | 50.2× | — | 15.9× | 44.7% | 83.0% | 31.7% | 77.8% | 29.9% | — | 4,193 |
| AKTX | $894.1B | — | — | — | — | — | — | -61.1% | -61.1% | — | 1 |
| JNJ | $650.5B | 24.5× | — | 6.9× | 6.0% | 67.9% | 28.5% | 32.9% | 20.7% | — | 4,451 |
| ABBV | $467.1B | 111.9× | 33.4× | 7.6× | 8.6% | 70.2% | 6.9% | -129% | 6.6% | 4.2× | 3,895 |
| MRK | $368.2B | 20.2× | — | 5.7× | 1.3% | 74.8% | 28.1% | 34.7% | 17.9% | — | 3,594 |
| UNH | $339.9B | 28.4× | 19.7× | 0.8× | 11.8% | 88.7% | 2.7% | 12.0% | 6.8% | 3.9× | 2,891 |
| AZN | $257.7B | — | — | — | — | — | — | — | — | — | 1,248 |
| TMO | $248.2B | 37.1× | 31.9× | 5.6× | 3.9% | — | 15.0% | 12.6% | 7.0% | 4.9× | 2,481 |
| AMGN | $204.6B | 26.7× | 17.6× | 5.6× | 10.0% | 67.2% | 21.0% | 89.1% | 12.2% | 3.8× | 3,014 |
| GILD | $187.3B | 22.3× | 20.4× | 6.4× | 2.4% | 78.8% | 28.9% | 37.5% | 17.9% | 2.4× | 2,218 |
| ABT | $178.0B | 27.5× | 19.2× | 4.0× | 5.7% | 56.4% | 14.7% | 12.5% | 10.0% | 1.4× | 2,964 |
| PFE | $157.1B | 20.3× | — | 2.5× | -1.6% | 74.3% | 12.4% | 9.0% | 5.1% | — | 2,838 |
| DHR | $150.2B | 42.1× | 31.0× | 6.1× | 2.9% | 59.1% | 14.7% | 6.9% | 5.1% | 3.4× | 2,083 |
| ISRG | $136.2B | 48.7× | 37.5× | 13.5× | 20.5% | 66.0% | 28.4% | 16.0% | 16.0% | — | 2,190 |
| VRTX | $131.1B | 33.7× | 28.8× | 10.9× | 8.9% | 86.2% | 32.9% | 21.2% | 21.2% | — | 1,609 |
| BMY | $127.8B | 18.2× | — | 2.6× | -0.2% | 71.1% | 14.6% | 38.2% | 11.1% | — | 2,431 |
| MDT | $118.8B | 24.9× | 12.6× | 3.3× | 8.4% | 65.0% | 13.2% | 9.7% | 9.4% | 0.2× | 2,114 |
| CVS | $114.7B | 64.9× | 11.5× | 0.3× | 7.8% | 45.0% | 0.4% | 2.4% | 2.4% | 0.0× | 1,795 |
| SYK | $107.1B | 33.4× | 18.4× | 4.3× | 11.2% | 64.0% | 12.9% | 14.5% | 8.5% | 2.5× | 2,196 |
| MCK | $102.5B | 22.9× | 16.2× | 0.3× | 12.4% | 3.6% | 1.2% | -219% | 109% | 1.0× | 1,946 |
| HCA | $96.4B | 15.1× | — | 1.3× | 7.1% | — | 9.0% | -113% | 16.8% | — | 1,346 |
| ELV | $91.4B | 16.4× | 15.5× | 0.5× | 12.5% | 89.4% | 2.8% | 12.9% | 7.6% | 4.2× | 1,397 |
| REGN | $82.6B | 19.0× | 19.8× | 5.8× | 1.0% | — | 31.4% | 14.4% | 13.6% | 0.5× | 1,336 |
| CI | $72.7B | 12.4× | 5.5× | 0.3× | 11.2% | 21.8% | 2.2% | 14.3% | 14.1% | 0.0× | 1,583 |
| BDX | $52.2B | 31.2× | 14.0× | 2.4× | 8.2% | 45.4% | 7.7% | 6.6% | 3.8% | 3.8× | 1,402 |
Peers = companies sharing BDX's sector (Healthcare) with collected SEC financials. Multiples use the most recent end-of-day close and latest fiscal-year fundamentals (trailing, not forward). Missing cells mean the peer never reported that line item, has no collected price, or has a non-positive denominator. Not investment advice.
Top 40 institutional holders — bubble size is position value, color is the move since last quarter. Hover any holder for detail.
Drag any bubble to rearrange · size = dollar value of the position
EOD close · as of 2026-09-17
How a revenue dollar becomes profit — FY2025
Each value shows its share of revenue below it (common-size).
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $21.84B 100.0% | $20.18B 100.0% | $19.37B 100.0% | $18.87B 100.0% | $19.13B 100.0% | $16.07B 100.0% | $17.29B 100.0% | $15.98B 100.0% | $12.09B 100.0% | $12.48B 100.0% |
| Cost of Revenue | $11.91B 54.6% | $11.05B 54.8% | $11.20B 57.8% | $10.39B 55.1% | $10.50B 54.9% | $9.28B 57.7% | $9.00B 52.1% | $8.71B 54.5% | $6.13B 50.7% | $6.49B 52.0% |
| Gross Profit | — | — | — | — | — | $7.58B 47.1% | $8.29B 47.9% | $7.27B 45.5% | $5.94B 49.1% | $5.99B 48.0% |
| Research & Development | $1.26B 5.8% | $1.19B 5.9% | $1.24B 6.4% | $1.26B 6.7% | $1.28B 6.7% | $1.04B 6.5% | $1.06B 6.1% | $1.00B 6.3% | $770.0M 6.4% | $828.0M 6.6% |
| Selling, General & Admin | $5.28B 24.2% | $4.86B 24.1% | $4.72B 24.4% | $4.71B 25.0% | $4.72B 24.7% | $4.18B 26.0% | $4.33B 25.1% | $4.02B 25.1% | $2.91B 24.1% | $3.00B 24.1% |
| Total Operating Expenses | $19.26B 88.2% | $17.78B 88.1% | $17.26B 89.1% | $16.59B 87.9% | $16.88B 88.2% | $15.16B 94.3% | $15.53B 89.8% | $14.47B 90.6% | $10.57B 87.4% | $11.05B 88.5% |
| Operating Income | $2.58B 11.8% | $2.40B 11.9% | $2.11B 10.9% | $2.28B 12.1% | $2.25B 11.8% | $912.0M 5.7% | $1.76B 10.2% | $1.51B 9.4% | $1.52B 12.6% | $1.43B 11.5% |
| Interest Expense | $613.0M 2.8% | $528.0M 2.6% | $452.0M 2.3% | $398.0M 2.1% | $469.0M 2.5% | $528.0M 3.3% | $639.0M 3.7% | $706.0M 4.4% | $521.0M 4.3% | $388.0M 3.1% |
| Interest & Investment Income | $38.0M 0.2% | $163.0M 0.8% | $49.0M 0.3% | $16.0M 0.1% | $9.0M 0.0% | $7.0M 0.0% | $12.0M 0.1% | $65.0M 0.4% | $76.0M 0.6% | $21.0M 0.2% |
| Other Income (Expense), net | -$123.0M -0.6% | -$28.0M -0.1% | -$46.0M -0.2% | -$117.0M -0.6% | -$99.0M -0.5% | $23.0M 0.1% | $43.0M 0.2% | $305.0M 1.9% | -$101.0M -0.8% | $11.0M 0.1% |
| Pretax Income | $1.88B 8.6% | $2.00B 9.9% | $1.66B 8.6% | $1.78B 9.4% | $1.69B 8.8% | $414.0M 2.6% | $1.18B 6.8% | $1.17B 7.3% | $976.0M 8.1% | $1.07B 8.6% |
| Income Tax Expense | $203.0M 0.9% | $300.0M 1.5% | $132.0M 0.7% | $148.0M 0.8% | $88.0M 0.5% | $62.0M 0.4% | -$57.0M -0.3% | $862.0M 5.4% | -$124.0M -1.0% | $97.0M 0.8% |
| Net Income | $1.68B 7.7% | $1.71B 8.4% | $1.48B 7.7% | $1.78B 9.4% | $2.09B 10.9% | $874.0M 5.4% | $1.23B 7.1% | $311.0M 1.9% | $1.10B 9.1% | $976.0M 7.8% |
| Per Share | ||||||||||
| EPS (Basic) | $5.83 | $5.88 | $4.97 | $5.93 | $6.92 | $2.75 | $4.01 | $0.62 | $4.70 | $4.59 |
| EPS (Diluted) | $5.82 | $5.86 | $4.94 | $5.88 | $6.85 | $2.71 | $3.94 | $0.60 | $4.60 | $4.49 |
| Weighted Avg Shares (Basic) | 287.6M | 289.8M | 286.3M | 285.0M | 289.3M | 279.0M | 269.9M | 258.4M | 218.9M | 212.7M |
| Weighted Avg Shares (Diluted) | 288.5M | 291.0M | 288.4M | 287.4M | 292.1M | 282.4M | 274.8M | 264.6M | 223.6M | 217.5M |
Source: SEC EDGAR XBRL filings (annual, fiscal year). Quarterly flow items are derived from cumulative filings; balance-sheet figures are as-of each period end. Ratios and margins are computed, not reported.
Is the value real, and is the business safe? Academic scores + earnings quality + solvency, from SEC filings.
6/7 of the 9 checks — 2 couldn't be scored (see above), so the score is out of the 7 with data.
Insufficient balance-sheet detail (needs retained earnings, working capital, equity).
Needs granular two-year detail (receivables, PP&E, D&A, SG&A) — not fully reported.
Cash-conversion data unavailable. Lower/negative accruals = higher quality (Sloan).
Interest coverage is thin — monitor; leverage falling year-over-year.
F-Score (0–9 fundamental momentum), Altman Z (distress risk), and Beneish M (earnings-manipulation screen) are academic models computed from the SEC filings. Screens and context — educational, not recommendations.
What the company returns to shareholders — and whether it's covered by cash.
Free-cash-flow coverage unavailable. Last year: $1.2B dividends + $1.0B buybacks = $2.2B returned.
1 consecutive years of dividend increases · 5%/yr.
Yields use the latest fiscal-year dividends/buybacks over current market cap. Dividends and buybacks from the SEC cash-flow statement; payout coverage vs net income and free cash flow. Educational — not a recommendation.
How management deployed cash over 10 years — and what it earned on reinvestment.
A reinvestment story — most cash went back into growth rather than to shareholders.
Modest payoff on reinvested capital. Current ROIC on all capital: 4%. Rough measure (includes maintenance capex).
Cash uses aggregated from the SEC cash-flow statement over 10 fiscal years. "Return on reinvestment" is a rough proxy — operating-income change ÷ cumulative CapEx + M&A — and includes maintenance capex. Educational — not a recommendation.
How much the company owes, how it's trended, and how comfortably it's serviced.
Cash of $567M is below the $2.2B due within a year — relies on refinancing or operating cash flow. Scheduled principal only (excludes interest & revolver draws). As of 2025-09-30 (10-K).
Green ≤ 1.5× · amber ≤ 3× · red > 3× (leverage relative to cash earnings).
Coverage is adequate but not comfortable. Effective rate ~3.2% on $19.2B of debt.
Cash of $567M is below short-term debt of $1.6B — relies on refinancing/operations.
Mostly long-term debt (balance-sheet current vs non-current split). See the maturity ladder above for the year-by-year repayment schedule.
Debt, cash, interest and equity from the SEC balance sheet & income statement. Effective rate = interest ÷ average debt. Maturity ladder from the SEC long-term-debt repayment schedule. Educational — not a recommendation.
EOD close · as of 2026-09-17
No standout strengths flagged.
Where each multiple sits in its own 14-yr range · 50th pct blended
Dot = today · shaded = middle 50% · line = median. Lower percentile = cheaper vs its own 14-yr history.
Is the profit real, and how strong is the balance sheet?
FY2025 · every deduction from revenue to net income
DuPont — the three levers
Watch the leverage lever — a chunk of ROE comes from the balance sheet.
What the company owes vs. what it holds
Year-by-year maturities aren't in SEC companyfacts (footnote-only), so this shows the debt/cash structure and net leverage instead.
Latest year: profit growth vs revenue growth
Low operating leverage — profit tracks sales closely (stable, less cyclical).
Each line as % of revenue — the trend in color
| % of revenue | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Cost of Revenue | 54.5 | 52.1 | 57.7 | 54.9 | 55.1 | 57.8 | 54.8 | 54.6 |
| Gross Profit | 45.5 | 47.9 | 47.1 | — | — | — | — | — |
| R&D | 6.3 | 6.1 | 6.5 | 6.7 | 6.7 | 6.4 | 5.9 | 5.8 |
| SG&A | 25.1 | 25.1 | 26.0 | 24.7 | 25.0 | 24.4 | 24.1 | 24.2 |
| Operating Income | 9.4 | 10.2 | 5.7 | 11.8 | 12.1 | 10.9 | 11.9 | 11.8 |
| Income Tax | 5.4 | -0.3 | 0.4 | 0.5 | 0.8 | 0.7 | 1.5 | 0.9 |
| Net Income | 1.9 | 7.1 | 5.4 | 10.9 | 9.4 | 7.7 | 8.4 | 7.7 |
Green = margin-favorable vs the row's own range · red = unfavorable.
The metrics that matter, over time
A 30-second read on BDX: price, valuation, headline fundamentals, and an auto-generated scorecard from SEC filings. Flags are rule-based signals, not recommendations.